<DOC>
	<DOC>NCT00002308</DOC>
	<brief_summary>To make stavudine (d4T) available to patients with advanced HIV disease for whom no alternative antiretroviral is satisfactory. To study the safety and efficacy of two dose levels in a twice-daily regimen.</brief_summary>
	<brief_title>A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<criteria>Inclusion Criteria Patients must have: HIV positivity with CD4 count &lt; 300 cells/mm3. Intolerance to or failure on approved antiretroviral therapy. Ability to provide informed consent (of parent or guardian if appropriate). NOTE: Incarcerated persons may be eligible to participate. Exclusion Criteria Coexisting Condition: Patients with the following symptoms or conditions are excluded: Grade 2 or worse diseaserelated peripheral neuropathy. Unresolved drugrelated peripheral neuropathy of any severity that is attributable to other nucleoside analogs (AZT, ddC, ddI). Malignancy likely to require systemic chemotherapy with myelosuppressive or neurotoxic drugs in the first 3 months of stavudine treatment. Pregnancy (physicians of pregnant patients may contact BristolMyers to determine eligibility for stavudine therapy in another protocol). Strongly discouraged: AZT, ddI, ddC, and other antiretroviral agents.</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Stavudine</keyword>
</DOC>